FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3106339718> ?p ?o ?g. }

• W3106339718 endingPage "100215" @default.
• W3106339718 startingPage "100215" @default.
• W3106339718 abstract "•In patients with HCC, the severity of coexisting liver dysfunction is usually categorised using the Child-Pugh system.•We demonstrate that the simpler albumin–bilirubin (ALBI) nomogram can be used for pre-treatment prognostication and on-treatment assessment.•Ramucirumab did not negatively impact on liver function compared to placebo in patients with advanced HCC and elevated AFP.•Liver-specific adverse events were reported more frequently in patients with more severe liver disfunction at baseline.•Ramucirumab provided a survival benefit irrespective of baseline liver function in patients with advanced HCC and elevated AFP. Background & AimsThe albumin–bilirubin (ALBI) grade/score is derived from a validated nomogram to objectively assess prognosis and liver function in patients with hepatocellular carcinoma (HCC). In this post hoc analysis, we assessed prognosis in terms of survival by baseline ALBI grade and monitored liver function during treatment with ramucirumab or placebo using the ALBI score in patients with advanced HCC.MethodsPatients with advanced HCC, Child-Pugh class A with prior sorafenib treatment were randomised in REACH trials to receive ramucirumab 8 mg/kg or placebo every 2 weeks. Data were analysed by trial and as a meta-analysis of individual patient-level data (pooled population) from REACH (alpha-fetoprotein ≥400 ng/ml) and REACH-2. Patients from REACH with Child-Pugh class B were analysed as a separate cohort. The ALBI grades and scores were calculated at baseline and before each treatment cycle.ResultsBaseline characteristics by ALBI grade were balanced between treatment arms among patients in the pooled population (ALBI-1, n = 231; ALBI-2, n = 296; ALBI-3, n = 7). Baseline ALBI grade was prognostic for overall survival (OS; ALBI grade 2 vs. 1; hazard ratio [HR]: 1.38 [1.13–1.69]), after adjusting for other significant prognostic factors. Mean ALBI scores remained stable in both treatment arms compared with baseline and were unaffected by baseline ALBI grade, macrovascular invasion, tumour response, geographical region, or prior locoregional therapy. Baseline ALBI grades 2 and 3 were associated with increased incidence of liver-specific adverse events and discontinuation rates in both treatments. Ramucirumab improved OS in patients with baseline ALBI grade 1 (HR 0.605 [0.445–0.824]) and ALBI grade 2 (HR 0.814 [0.630–1.051]).ConclusionsCompared with placebo, ramucirumab did not negatively impact liver function and improved survival irrespective of baseline ALBI grade.Lay summaryHepatocellular carcinoma is the third leading cause of cancer-related death worldwide. Prognosis is affected by many clinical factors including liver function both before and during anticancer treatment. Here we have used a validated approach to assess liver function using 2 laboratory parameters, serum albumin and bilirubin (ALBI), both before and during treatment with ramucirumab in 2 phase III placebo-controlled studies. We confirm the practicality of using this more simplistic approach in assessing liver function prior to and during anticancer therapy, and demonstrate ramucirumab did not impair liver function when compared with placebo. The albumin–bilirubin (ALBI) grade/score is derived from a validated nomogram to objectively assess prognosis and liver function in patients with hepatocellular carcinoma (HCC). In this post hoc analysis, we assessed prognosis in terms of survival by baseline ALBI grade and monitored liver function during treatment with ramucirumab or placebo using the ALBI score in patients with advanced HCC. Patients with advanced HCC, Child-Pugh class A with prior sorafenib treatment were randomised in REACH trials to receive ramucirumab 8 mg/kg or placebo every 2 weeks. Data were analysed by trial and as a meta-analysis of individual patient-level data (pooled population) from REACH (alpha-fetoprotein ≥400 ng/ml) and REACH-2. Patients from REACH with Child-Pugh class B were analysed as a separate cohort. The ALBI grades and scores were calculated at baseline and before each treatment cycle. Baseline characteristics by ALBI grade were balanced between treatment arms among patients in the pooled population (ALBI-1, n = 231; ALBI-2, n = 296; ALBI-3, n = 7). Baseline ALBI grade was prognostic for overall survival (OS; ALBI grade 2 vs. 1; hazard ratio [HR]: 1.38 [1.13–1.69]), after adjusting for other significant prognostic factors. Mean ALBI scores remained stable in both treatment arms compared with baseline and were unaffected by baseline ALBI grade, macrovascular invasion, tumour response, geographical region, or prior locoregional therapy. Baseline ALBI grades 2 and 3 were associated with increased incidence of liver-specific adverse events and discontinuation rates in both treatments. Ramucirumab improved OS in patients with baseline ALBI grade 1 (HR 0.605 [0.445–0.824]) and ALBI grade 2 (HR 0.814 [0.630–1.051]). Compared with placebo, ramucirumab did not negatively impact liver function and improved survival irrespective of baseline ALBI grade." @default.
• W3106339718 created "2020-11-23" @default.
• W3106339718 creator A5006848714 @default.
• W3106339718 creator A5009529288 @default.
• W3106339718 creator A5022537134 @default.
• W3106339718 creator A5025272654 @default.
• W3106339718 creator A5027112485 @default.
• W3106339718 creator A5027983969 @default.
• W3106339718 creator A5032900701 @default.
• W3106339718 creator A5033735284 @default.
• W3106339718 creator A5039119608 @default.
• W3106339718 creator A5046498356 @default.
• W3106339718 creator A5046542801 @default.
• W3106339718 creator A5049693589 @default.
• W3106339718 creator A5060428080 @default.
• W3106339718 creator A5062301570 @default.
• W3106339718 creator A5068055005 @default.
• W3106339718 creator A5073989429 @default.
• W3106339718 creator A5079645039 @default.
• W3106339718 creator A5083536113 @default.
• W3106339718 creator A5084442967 @default.
• W3106339718 creator A5086023651 @default.
• W3106339718 creator A5088566246 @default.
• W3106339718 date "2021-04-01" @default.
• W3106339718 modified "2023-10-18" @default.
• W3106339718 title "Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2" @default.
• W3106339718 cites W1544233162 @default.
• W3106339718 cites W1828082159 @default.
• W3106339718 cites W1937746457 @default.
• W3106339718 cites W1966976587 @default.
• W3106339718 cites W1971837077 @default.
• W3106339718 cites W2016828736 @default.
• W3106339718 cites W2044702943 @default.
• W3106339718 cites W2067917838 @default.
• W3106339718 cites W2084139018 @default.
• W3106339718 cites W2097494822 @default.
• W3106339718 cites W2103925554 @default.
• W3106339718 cites W2114012800 @default.
• W3106339718 cites W2118868641 @default.
• W3106339718 cites W2119190881 @default.
• W3106339718 cites W2120579447 @default.
• W3106339718 cites W2138289424 @default.
• W3106339718 cites W2138787512 @default.
• W3106339718 cites W2153297361 @default.
• W3106339718 cites W2169824120 @default.
• W3106339718 cites W2192368460 @default.
• W3106339718 cites W2224548528 @default.
• W3106339718 cites W2318933482 @default.
• W3106339718 cites W2396589869 @default.
• W3106339718 cites W2521441342 @default.
• W3106339718 cites W2560499218 @default.
• W3106339718 cites W2582507973 @default.
• W3106339718 cites W2591717879 @default.
• W3106339718 cites W2604979870 @default.
• W3106339718 cites W2605592675 @default.
• W3106339718 cites W2737883024 @default.
• W3106339718 cites W2758905766 @default.
• W3106339718 cites W2761293277 @default.
• W3106339718 cites W2769966173 @default.
• W3106339718 cites W2776090439 @default.
• W3106339718 cites W2787358630 @default.
• W3106339718 cites W2799971114 @default.
• W3106339718 cites W2806442883 @default.
• W3106339718 cites W2807976962 @default.
• W3106339718 cites W2809889937 @default.
• W3106339718 cites W2889646458 @default.
• W3106339718 cites W2905083507 @default.
• W3106339718 cites W2908573150 @default.
• W3106339718 cites W2937354878 @default.
• W3106339718 cites W2938130363 @default.
• W3106339718 cites W2945004896 @default.
• W3106339718 cites W2946805373 @default.
• W3106339718 cites W2955378739 @default.
• W3106339718 cites W2962119120 @default.
• W3106339718 cites W4294214983 @default.
• W3106339718 cites W569106485 @default.
• W3106339718 doi "https://doi.org/10.1016/j.jhepr.2020.100215" @default.
• W3106339718 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7772786" @default.
• W3106339718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33392490" @default.
• W3106339718 hasPublicationYear "2021" @default.
• W3106339718 type Work @default.
• W3106339718 sameAs 3106339718 @default.
• W3106339718 citedByCount "28" @default.
• W3106339718 countsByYear W31063397182020 @default.
• W3106339718 countsByYear W31063397182021 @default.
• W3106339718 countsByYear W31063397182022 @default.
• W3106339718 countsByYear W31063397182023 @default.
• W3106339718 crossrefType "journal-article" @default.
• W3106339718 hasAuthorship W3106339718A5006848714 @default.
• W3106339718 hasAuthorship W3106339718A5009529288 @default.
• W3106339718 hasAuthorship W3106339718A5022537134 @default.
• W3106339718 hasAuthorship W3106339718A5025272654 @default.
• W3106339718 hasAuthorship W3106339718A5027112485 @default.
• W3106339718 hasAuthorship W3106339718A5027983969 @default.
• W3106339718 hasAuthorship W3106339718A5032900701 @default.
• W3106339718 hasAuthorship W3106339718A5033735284 @default.
• W3106339718 hasAuthorship W3106339718A5039119608 @default.
• W3106339718 hasAuthorship W3106339718A5046498356 @default.

• next